Highlights
- Third quarter total revenues were USD 127,655 thousand against USD 110,329 thousand.
- The net loss narrowed to USD 737 thousand from USD 969 thousand.
- IBSRELA Revenue was USD 96.3 million, up 23%.
- Full year IBSRELA guidance of USD 350 million to USD 370 million was reaffirmed.
Ardelyx, Inc. (NASDAQ:ARDX) shares were trading near their 52-week low at USD 2.94 on November 6, 2026, down 1.84% on the day. The company reported third quarter total revenues of USD 127,655 thousand, up about 16%, and a net loss of USD 737 thousand.
Ardelyx has a market Capitalization of about USD 737.78 million at the current price. Management said its two first in class medicines, IBSRELA and XPHOZAH, generated over USD 125 million in revenue in the quarter, up 19% from a year ago.
Third Quarter Results
Total revenues were USD 127,655 thousand against USD 110,329 thousand. Income from operations was USD 4,023 thousand against USD 4,668 thousand. The net loss was USD 737 thousand against USD 969 thousand, and the loss per share was USD 0.00 in both periods. Management said R&D expenses were USD 25.2 million against USD 18.1 million.
Product Detail
IBSRELA revenue was USD 96.3 million, an increase of 23%. XPHOZAH revenue was USD 29.2 million, up 7%, with paid prescriptions up 22% from the same quarter in 2025. The filing records higher Demand and higher net price for XPHOZAH, and Royalty licensing revenue from Fosun Pharma. Management also described a targeted Advertising campaign intended to reach more than 10 million people through outlets such as Netflix, Hulu, Prime Video and Disney.
Nine-Month Results
Total revenues were USD 343,005 thousand against USD 282,105 thousand. The loss from operations was USD 41,195 thousand against USD 46,076 thousand, and the net loss was USD 55,063 thousand against USD 61,192 thousand, or USD 0.22 per share against USD 0.25.
Guidance
Management reaffirmed full year 2026 IBSRELA guidance of USD 350 million to USD 370 million. It continues to expect full year 2026 operating expenses to be below USD 500 million.
Cash Flow and Balance Sheet
Cash and cash equivalents were USD 46,317 thousand against USD 67,999 thousand at December 31, 2025. For the nine months, net cash used in Operating Activities was USD 36,465 thousand against USD 63,434 thousand, and net cash provided by financing activities was USD 56,121 thousand against USD 53,952 thousand.
Total Assets were USD 587,525 thousand against USD 501,604 thousand. Total liabilities were USD 423,479 thousand against USD 334,655 thousand, and total stockholders' Equity was USD 164,046 thousand against USD 166,949 thousand. The accumulated Deficit was USD 1,002,002 thousand. There were 251,372,553 shares outstanding as of October 27, 2026.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...